The Intricate Interaction Between Expectations and Therapeutic Outcomes of Psychedelic Agents. [PDF]
JAMA Psychiatry, 2023 This Viewpoint explores how expectations influence outcomes of psychedelic drug therapy.
Colloca L, Nikayin S, Sanacora G.
europepmc +3 more sources
Psychedelic Agents as Potential Therapeutics for Obsessive Compulsive Disorder
Impulse: The Premier Undergraduate Neuroscience Journal, 2022 Obsessive-Compulsive Disorder (OCD) is a chronic psychiatric anxiety disorder distinguished by obsessive thoughts and repetitious actions. Current therapies for OCD are not very effective and have many possible side-effects.
Josh Nagra
doaj +1 more source
Current perspectives on psychedelic treatments in Europe [PDF]
The Lancet Regional Health. EuropeSummary: In this viewpoint, we explore the evolving landscape of psychedelic-assisted therapy in Europe, focusing on clinical, regulatory, and therapeutic developments.
Santiago Madero +4 more
doaj +2 more sources
SSM: Qualitative Research in Health, 2023 Clinical and basic science research with psychedelics is a nascent but rapidly growing field. Historically, psychedelics research has faced setbacks due to overenthusiasm, methodological challenges, and conflicting worldviews.
Michaela Barber +2 more
doaj +2 more sources
Novel Indoline Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness and CNS Disorders. [PDF]
ACS Med Chem LettProvided herein are novel indoline derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders and processes for preparing such compounds.
Sabnis RW, Sabnis AR.
europepmc +3 more sources
Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders. [PDF]
ACS Med Chem Lett, 2021 Kargbo RB.
europepmc +4 more sources
Novel 3-Cycloaminoindole Compounds as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders. [PDF]
ACS Med Chem LettProvided herein are novel 3-cycloaminoindole compounds as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders and processes for preparing such compounds.
Sabnis RW.
europepmc +3 more sources
1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents - A Review. [PDF]
ACS Pharmacol Transl Sci1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI, or DOX where X = -I) was first synthesized in 1973 in a structure-activity study to explore the effect of various aryl substituents on the then newly identified, and subsequently controlled, hallucinogenic agent 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM, or DOX where X = -CH3).
Glennon RA, Dukat M.
europepmc +3 more sources
South African Medical Journal, 2023 Healthcare providers face the challenging task of managing patients who suffer from chronic nociplastic pain conditions. Pain is a multidimensional experience, and the current approach to managing people in chronic pain often fails to meet the needs
J Van Der Walt, R Parker
doaj +4 more sources
Psychedelics in Multiple Sclerosis: Mechanisms, Challenges, and Prospects for Neuroimmune Modulation and Repair [PDF]
CellsMultiple Sclerosis (MS) therapies effectively modulate peripheral immune responses but largely fail to promote neural repair within the central nervous system.
Ivan Anchesi +8 more
doaj +2 more sources